405 related articles for article (PubMed ID: 28575060)
21. Evaluating drug resistance in visceral leishmaniasis: the challenges.
Hendrickx S; Guerin PJ; Caljon G; Croft SL; Maes L
Parasitology; 2018 Apr; 145(4):453-463. PubMed ID: 27866478
[TBL] [Abstract][Full Text] [Related]
22. Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.
Hendrickx S; Bulté D; Van den Kerkhof M; Cos P; Delputte P; Maes L; Caljon G
Int J Parasitol Drugs Drug Resist; 2019 Apr; 9():1-7. PubMed ID: 30562667
[TBL] [Abstract][Full Text] [Related]
23. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
24. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
25. Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.
Subba Raju BV; Gurumurthy S; Kuhls K; Bhandari V; Schnonian G; Salotra P
Parasitol Res; 2012 Oct; 111(4):1559-68. PubMed ID: 22752721
[TBL] [Abstract][Full Text] [Related]
26. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
[TBL] [Abstract][Full Text] [Related]
27. Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition.
Bulté D; Van Bockstal L; Dirkx L; Van den Kerkhof M; De Trez C; Timmermans JP; Hendrickx S; Maes L; Caljon G
PLoS Negl Trop Dis; 2021 Jul; 15(7):e0009622. PubMed ID: 34292975
[TBL] [Abstract][Full Text] [Related]
28. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.
Dube A; Singh N; Sundar S; Singh N
Parasitol Res; 2005 Jun; 96(4):216-23. PubMed ID: 15868188
[TBL] [Abstract][Full Text] [Related]
29. 15d-Prostaglandin J2 induced reactive oxygen species-mediated apoptosis during experimental visceral leishmaniasis.
Vishwakarma P; Parmar N; Yadav PK; Chandrakar P; Kar S
J Mol Med (Berl); 2016 Jun; 94(6):695-710. PubMed ID: 26830627
[TBL] [Abstract][Full Text] [Related]
30. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
31. A mitochondrial HSP70 (HSPA9B) is linked to miltefosine resistance and stress response in Leishmania donovani.
Vacchina P; Norris-Mullins B; Carlson ES; Morales MA
Parasit Vectors; 2016 Dec; 9(1):621. PubMed ID: 27906059
[TBL] [Abstract][Full Text] [Related]
32. Functional Involvement of Leishmania donovani Tryparedoxin Peroxidases during Infection and Drug Treatment.
Das S; Giri S; Sundar S; Shaha C
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061756
[TBL] [Abstract][Full Text] [Related]
33. Miltefosine enhances the fitness of a non-virulent drug-resistant Leishmania infantum strain.
Eberhardt E; Bulté D; Van Bockstal L; Van den Kerkhof M; Cos P; Delputte P; Hendrickx S; Maes L; Caljon G
J Antimicrob Chemother; 2019 Feb; 74(2):395-406. PubMed ID: 30412253
[TBL] [Abstract][Full Text] [Related]
34. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
35. Novel Agents against Miltefosine-Unresponsive Leishmania donovani.
Das M; Saha G; Saikia AK; Dubey VK
Antimicrob Agents Chemother; 2015 Dec; 59(12):7826-9. PubMed ID: 26392497
[TBL] [Abstract][Full Text] [Related]
36. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
37. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
38. Impaired development of a miltefosine-resistant Leishmania infantum strain in the sand fly vectors Phlebotomus perniciosus and Lutzomyia longipalpis.
Van Bockstal L; Sádlová J; Suau HA; Hendrickx S; Meneses C; Kamhawi S; Volf P; Maes L; Caljon G
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():1-7. PubMed ID: 31525614
[TBL] [Abstract][Full Text] [Related]
39. Eugenol derived immunomodulatory molecules against visceral leishmaniasis.
Charan Raja MR; Velappan AB; Chellappan D; Debnath J; Kar Mahapatra S
Eur J Med Chem; 2017 Oct; 139():503-518. PubMed ID: 28826085
[TBL] [Abstract][Full Text] [Related]
40. Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes.
Mondelaers A; Sanchez-Cañete MP; Hendrickx S; Eberhardt E; Garcia-Hernandez R; Lachaud L; Cotton J; Sanders M; Cuypers B; Imamura H; Dujardin JC; Delputte P; Cos P; Caljon G; Gamarro F; Castanys S; Maes L
PLoS One; 2016; 11(4):e0154101. PubMed ID: 27123924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]